Global Targeted Cancer Therapy Market Potential Examined in New Report Published at

23 Feb 2012 • by Natalie Aster

LONDON – How many products are profiled treating lung, breast and colorectal cancer? Which developmental pathways are much fancied to provide significant clinical advances and which companies are involved? BMS, Eli Lilly, Roche, and Takeda all have five or more late-stage products expected to launch – what are they, what do they target and when are they expected? What are the prospects for Teva Pharmaceutical Industries’ oncology portfolio? Emerging opportunities: with whom are the smaller companies working and how many have yet to secure development/marketing collaborations? Answers to all these key questions and many more can be found in the research report.

New market research report “Targeted Cancer Drugs The Launch Landscape to 2018” elaborated by Espicom Business Intelligence provides a complete assessment of the targeted cancer therapy landscape. Its scope comprises:

  • current state of the market for targeted cancer drugs, with an overview of both products; 
  • 79 new candidates that are currently under a minimum of Phase II development for solid tumours and a timeline detailing estimated launch dates to 2018; 
  • molecular targets on which industry attention is focused, and the companies involved in the development and commercialization of the products directed against these targets; 
  • individual assessment of each product in terms of its mode of action, current developmental status, clinical data, risks associated with development, developer and potential competition within the marketplace.

Report Details:

Targeted Cancer Drugs The Launch Landscape to 2018
Published: February, 2012
Pages: 306
Price: US$ 2.265,00

More new market research reports by the publisher can be found at Espicom Business Intelligence page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970